A novel application of triclabendazole, traditionally an antiparasitic drug, has demonstrated promising activity against lung cancer by targeting the enzyme Pyruvate Kinase M2 (PKM2). This metabolic intervention impairs cancer cell energy production and proliferation. The findings open avenues for repurposing existing drugs with known safety profiles in oncology, potentially offering effective adjunct therapies to combat lung tumor progression.